Scott Braunstein

Dr. Braunstein has served as an Operating Partner of Aisling since 2015. He was appointed Chief Executive Officer of Marinus Pharmaceuticals in August 2019, executive chairman in February 2019, and has served on the Board since September 2018. Prior to his current leadership role at Marinus, he was Chief Operating Officer and Chief Strategy Officer at Pacira Pharmaceuticals, Inc. From 2002 to 2014, Dr. Braunstein worked as a Healthcare Analyst and Portfolio Manager at J.P. Morgan Asset Management, where he invested in and conducted diligence on a wide variety of pharmaceutical products and product candidates. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as Assistant Clinical Professor at Albert Einstein College of Medicine and Columbia University Medical Center. He completed his training at The New York Hospital-Cornell Medical Center.

Dr. Braunstein currently serves on the board of Trevana Inc. and Constellation Pharmaceuticals. He previously served as board member of Ziopharm Oncology Inc., Esperion Pharmaceuticals, and Protara Therapeutics Inc.

Dr. Braunstein received his M.D. from the Albert Einstein College of Medicine and his B.S. from Cornell University.